Moderna RSV Vaccine Approval Delayed by FDA: What This Means for the Pharmaceutical Giant
Moderna RSV vaccine, FDA delay, vaccine approval process, mRNA-1345, RSV vaccine market, Moderna stock, pharmaceutical investment, vaccine efficacy, prefilled syringe advantage, Moderna FDA update The FDA has postponed its decision on Moderna’s mRNA-1345 RSV vaccine to the end of May due to administrative constraints. Explore what this delay means for Moderna, its investors, and the … Read more